The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 Elan Corp plc  (ELN) Trade Now »     Rate ELN  -  Discuss ELN  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
73.0%
Top:
0.0%
Rate ELN:



ELN Analysis & Videos »


ELN: Bull or Bear?

Newron Pharma ...Very attractive CNS-Pipeline Graphic_rating_buy ELN
N/A
 -3.08%
in 209 days
Newron Pharma (NRWN.SW) Listed on Swiss Exchange

M-Cap : 99,97 Mio CHF ( 88,26 Mio US$ )
Cash : 62,38 Mio CHF ( 55,07 Mio US$ )
Price : 16 CHF

Shares Out : 6,03 Mio


Pipeline
http://www.newron.com/uploads/pipeline_111November3.pdf


Safinamide Significantly Improved Motor Function in Patients with
Advanced Parkinson's Disease in a Phase III Pivotal Trial
<> <>http://www.newron.com/uploads/SAfinamidePIIIresultsNew...
By  biotech-freak   (-1.54%  risk: conservative)  05/13/09 Comment


Newron Pharma ...Very attractive CNS-Pipeline Graphic_rating_buy ELN
N/A
 +0.00%
in 0 minute
(closed on 05/13/09)
Newron Pharma (NRWN.SW) Listed on Swiss Exchange

M-Cap : 99,97 Mio CHF ( 88,26 Mio US$ )
Cash : 62,38 Mio CHF ( 55,07 Mio US$ )
Price : 16 CHF

Shares Out : 6,03 Mio


Pipeline
http://www.newron.com/uploads/pipeline_111November3.pdf


Safinamide Significantly Improved Motor Function in Patients with
Advanced Parkinson's Disease in a Phase III Pivotal Trial
<> <>http://www.newron.com/uploads/SAfinamidePIIIresultsNew...
By  biotech-freak   (-1.54%  risk: conservative)  05/13/09 Comment


Biotech no longer a safe haven: Elan (ELN) falls on hard times Graphic_rating_sell ELN
+11.17%
in 360 days

Filed under: Pfizer (PFE), Newsletters, Merck and Co (MRK), Stocks to Sell

It's been a tough year for many industries -- there's no denying it. Retailers of all stripes, oil companies, construction firms, financials, basic materials companies -- you name it, it's down.

So, are there any safe havens?

Historically, in times of economic uncertainty the pharmaceutical industry, along with consumer staples, is often the "go to" place where, at a minimum, you can count on a nice dividend yield to shield your portfolio from gigantic losses. Not anymore.

<>In this downturn even stalwarts such as Merck (...
By  Jamie Dlugosch   (+43.84%  risk: conservative)  12/12/08 Comment


Get free stock alert for ELN:
Your Email Address:


Biogen Reports Another PML Case in Tysabri Patient Graphic_rating_buy ELN
Mikerun
73%
 -2.17%
in 403 days

Biogen Reports Another PML Case in Tysabri Patient

<>
After the market close, Biogen (BIIB) filed an 8-K with the SEC reporting a new case of the potentially fatal brain disease known as PML or progressive multifocal leukoencephalopathy in a patient receiving their multiple sclerosis [MS] drug Tysabri, adding to the two new cases which were reported previously in July. Biogen is currently trading down by about 15% after hours while marketing partner Elan (ELN) is down by about 25% as of 5:15 PM. The news adds more uncertainty to Tysabri, which was removed from th...
By  Mike Havrilla   (+1.04%  risk: conservative)  10/30/08 1 comment


Biogen Reports Another PML Case in Tysabri Patient Graphic_rating_sell ELN
Mikerun
73%
 +0.00%
in 3 hours
(closed on 10/30/08)

Biogen Reports Another PML Case in Tysabri Patient

<>
After the market close, Biogen (BIIB) filed an 8-K with the SEC reporting a new case of the potentially fatal brain disease known as PML or progressive multifocal leukoencephalopathy in a patient receiving their multiple sclerosis [MS] drug Tysabri, adding to the two new cases which were reported previously in July. Biogen is currently trading down by about 15% after hours while marketing partner Elan (ELN) is down by about 25% as of 5:15 PM. The news adds more uncertainty to Tysabri, which was removed from th...
By  Mike Havrilla   (+1.04%  risk: conservative)  10/29/08 Comment


Clarity on Tysabri Makes Elan and Biogen a Buy Graphic_rating_buy ELN
Rxlogo
50%
 -51.39%
in 457 days

FDA Table of Potential Drug Risks - from Adverse Event Reporting System (AERS)

<> The FDA has published a table with the names of products and potential signals of serious risks and/or new safety information identified for these products during 1Q08 in the AERS database. The FDA notes that patients should not stop taking these medications and should consult their prescriber with any questions as the agency will investigate each of the claims further before taking action or issuing more definitive statements on the reported concerns. Some highlights from this table of produ...
By  Mike Havrilla   (-9.03%  risk: conservative)  09/06/08 Comment


Clarity on Tysabri Makes Elan and Biogen a Buy Graphic_rating_buy ELN
Mikerun
73%
 -50.31%
in 53 days
(closed on 10/29/08)

FDA Table of Potential Drug Risks - from Adverse Event Reporting System (AERS)

<> The FDA has published a table with the names of products and potential signals of serious risks and/or new safety information identified for these products during 1Q08 in the AERS database. The FDA notes that patients should not stop taking these medications and should consult their prescriber with any questions as the agency will investigate each of the claims further before taking action or issuing more definitive statements on the reported concerns. Some highlights from this table of produ...
By  Mike Havrilla   (+1.04%  risk: conservative)  09/06/08 Comment


Biogen (BIIB): A 'dirt cheap' biotech bet Graphic_rating_buy ELN
-53.09%
in 469 days

Filed under: Newsletters, Stocks to Buy

"If you want to buy a great company dirt cheap, think Biogen Idec (NASDAQ: BIIB)," says biotech expert Michael Shulman. Here's an update from ChangeWave Biotech Investor.

"Biogen recently got hammered on 'bad' news that wasn't actually so bad. BIIB and partner Elan (NYSE: ELN) reported that two MS patients, out of 31,800 currently receiving Tysabri, developed a rare brain malady called PML.

<>"It's important to note, here, that the two companies had predicted that one in 1000 cases could develop PML and the FDA let the drug come to market with this unders...
By  Steven Halpern   (+5.46%  risk: moderate)  08/25/08 Comment


Get free stock alert for ELN:
Your Email Address:


Biogen-Idec, Elan: Panic Selling Creates Interesting Opportunity Graphic_rating_buy ELN
-43.04%
in 483 days

In July, Biogen-Idec (BIIB) and Elan (ELN), who co-market the multiple sclerosis drug Tysabri, announced two new cases of PML, a potentially deadly side effect. The stocks sold-off almost entirely. Biogen-Idec lost about 30% of its market share while Elan has lost over two thirds of its value.

I had previously recommended shares of Biogen-Idec right after the buyout rumors vanished and the stock was trading around 54. I had based that recommendation on the potential success of Tysabri.
By  A. Reza Saadat   (-26.53%  risk: conservative)  08/11/08 Comment


Elan is way down and I'm buying Graphic_rating_buy ELN
Astukphoto
22%
 -46.11%
in 489 days
Today's stock selection:
ELN Elan
žInspired by:

Elan is way down and I'm buying

http://articles.moneycentral.msn.com/Investing/StrategyLab/Rn...

I'm buying drug maker Elan ( ELN , news , msgs ) even though it is down more than 60% in the last three days. Here's why:

Alzheimer's test results: Pass or fail?

The first big drop came after the markets closed last Tuesday, when Elan detailed the results of its Phase 2 trial for bapineuzumab, a potential new drug for Alzheimer's disease. The company had previously announced that the Phase 2 trial did ...
By  Armin Stuk   (-18.72%  risk: moderate)  08/05/08 1 comment


Elan: Actionable Buy Call Graphic_rating_buy ELN
-67.91%
in 495 days

Leerink Swann is out defending Elan (ELN) saying they are making no changes to their valuation of ELN shares and view any weakness today as a buying opportunity.

The harsh sell off in the stock that could occur today will likely be fueled by overblown expectations for the Phase II data and the difficulty in presenting a cogent analysis of a complex trial in a complex disease in a 12-minute presentation.
By  Notable Calls   (-6.89%  risk: aggressive)  07/30/08 Comment


Elan Corp plc Graphic_rating_buy ELN
Foto
62%
 -81.62%
in 531 days

Analyst Buy Call Of The Day

Goldman Sach added Elan Corp. plc (NYSE: ELN ) to its 'market moving' Conviction Buy List.  The firm cited prospects of the company's Alzheimer's drug bapineuzumab.

Elan is up 4.5% in afternoon trading.

More From Goldman Sachs' Conviction Buy List: http://www.streetinsider.com/entities/Goldman+Sachs+Convictio...

By  Marian Filo   (-24.55%  risk: aggressive)  06/24/08 2 comments


Tysabri gets initial apporval Graphic_rating_buy ELN
Buddy_icon
14%
 +7.77%
in 13 days
(closed on 01/31/08)
Elan, one of Ireland's biggest pharma companies, has announced that it has gained approval to test it's Tysabri treatment for Multiple Sclerosis.  If this drug is a success, it could mean up to 1.1BN additional revenue for Elan and partner company Biogen (source: http://www.forbes.com/feeds/ap/2008/01/17/ap4542688.html ).  Here is the news story:


US approval for Elan’s Tysabri

Go ahead for controversial drug to treat Crohn’s disease

By Triona Doherty

<> Athlone-based company Elan have been given the go ahead this week to market their drug Tysabri in the ...
By  shaneh2   (-10.07%  risk: moderate)  01/18/08 Comment


ELAN a company with an idea. Graphic_rating_buy ELN
N/A
 -68.07%
in 867 days
Iam semi new to this whole stock market scene but since i was in 11th grade i have been watching Elan i own a nice amount of shares in the company and bought early in the 12's i always say to myself i should sell. Recently the stock climbed to the mid 22's Now its back in the 19's. Their drug Tysabri is a drug in which can be expected to generate more revenue then expense. In order for this company to soar over the other biotech stocks this drug must succeed. From the trials it has under gone so far it looks promising. BUY NOW before too late and do not let go until ur in the 30's.
By  Stockkid   (-68.07%  risk: aggressive)  07/24/07 Comment


Fundamental analysis Graphic_rating_buy ELN
29%
 -57.75%
in 941 days
Tysabri (to reduce the probability of MS recuringr) is continuing to increase in usage after being taken off the market due to safety issues (deaths) when used with Avonex or immunosuppressive drugs.  This is a potential billion dollar drug. Elan shares revenue with Biogen IDEC.  On the horizon is the start of phase III trials of an Altzheimer drug with Wyeth.  This drug could change the shape of Wyeth and Elan.  So far, the safety and effectiveness seems ok although phase II results are not all out.  This could be a 10 Billion per year drug.
By  art mcgill   (-11.42%  risk: aggressive)  05/11/07 Comment





People Bullish on ELN

rogalinski
Analyst
N/A
about 1 mo ago

jgj
Analyst
N/A
2 mos ago

georgejjl
Analyst
N/A
3 mos ago

450vampyr_avatar-med
supratrader
Principal
N/A
4 mos ago

biotech-freak
Analyst
N/A
6 mos ago


People Bearish on ELN

dickj
Analyst
N/A
6 mos ago

Jamie Dlugosch
Tracked Blogger
78%
12 mos ago

xiongyp
Analyst
64%
about 1 year ago

mlgeorge
Analyst
N/A
about 1 year ago

mrwhite2u
Analyst
81%
over 2 years ago

ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.63% 381
2 Gerald Greene 18.14 +67.11% 211
3 stockmarketfunding.com 17.66 +25.66% 55
4 akiralegrand 13.47 +14.32% 62
5 anup2104 12.13 +74.38% 40


POPULAR STOCKS
Symbol Company Name Sentiment
DELL Dell Inc
GLD streetTRACKS Gold
WMT WalMart Stores Inc
INTC Intel Corp
MA MasterCard Inc
FSLR First Solar Inc.

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on ELN


Discussion Wall + Add  
tanumoy   (+123.35%  risk: conservative)
Upcoming data of an Alzheimer's drug to be presente.. - A small cap company is going to be presenting data on their Alzheimer's drug at the Alzheimer's conference in July. The results of this clinical trial...
+   0 replies


More Resources

Graphic_arrow1 About Elan Corp plc - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch